The European Commission's Committee on Medicines has recommended approval of Merck's KEYTRUDA as a mototherapy for colorectal cancer in patients with MSI-H and dMMR tumors. The European Commission's decision is expected in early 2021. According to statistics, about 1.85 million new cases of such cancer were reported worldwide in 2018, including 0.5 million in Europe.
The European Commission's Committee on Medicines has recommended approval of Merck's KEYTRUDA as a mototherapy for colorectal cancer in patients with MSI-H and dMMR tumors. The European Commission's decision is expected in early 2021. According to statistics, about 1.85 million new cases of such cancer were reported worldwide in 2018, including 0.5 million in Europe. 
merck.com
English (US) 